Todays Play Is Viral Genetics` (VRAL.PK )

Good morning everyone.

Viral Genetics` P-IND Clears FDA To Commence Clinical Trials in Humans Set to Begin First Ovarian Cancer Study Test Site for Metabolic Disruption Technology (MDT) Combination Therapy A physician-initiated Investigational New Drug (P-IND) application submitted to the FDA in late April, 2012, has cleared the FDA`s screening process with the requirement for a regular IND application being waived, resulting in the company being able to begin the first of at least two proposed clinical trial sites to investigate a potential oncology treatment developed from Viral Genetics` (Pinksheets:VRAL.PK - News) Metabolic Disruption Technology (MDT), which is licensed exclusively to the Company. The P-IND - part of a larger, coordinated research effort - was submitted by the first test site at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, which includes patient enrollment at Scott and White Hospital (S&W) in Temple, Texas.

Additional test sites may also be added in the future.

 - Read The Full Release Viral Genetics, Inc. (OTCPK: VRAL) is a biotechnology research and development company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: "Targeted Peptides" and "Metabolic Disruption". As we near completion of our preclinical research, we are preparing pre-IND applications for FDA clinical trials of compounds from these approaches in the US.

 VRAL`s vision is to build on the innovative research being conducted by Dr. M. Karen Newell- Rogers, by developing the technology from the laboratory stage through to clinical trials and seeking partners for late-stage clinical development. Dr. Newell-Rogers`s work in the areas of Targeted Peptides Technology (TPT) and Metabolic Disruption Technology (MDT) are revealing new facets of many diseases and the bodys response to them. In doing so, we believe that her work is outlining solutions to some of the world`s major health challenges including HIV/AIDS, drug-resistant cancers and autoimmune disease.

 Viral Genetics entered into a series of agreements with the University of Colorado and Dr. Newell-Rogers that, over time and after much successful hard work, culminated in the two Exclusive License Agreements that now form the basis of our intellectual property portfolio and our ongoing R&D efforts. Part of this included expanding our technology to include a new line of research relating to Metabolic Disruption (MDT) - an area that holds promise in cancer therapy, wound healing and - to our surprise - production of plant oils and biofuels.?? VRAL is now focused on initiating clinical trial testing of compounds for HIV/AIDS, Lyme Disease, Staphylococcus, Streptococcus and Sepsis infection, glioblastoma (a form of brain cancer), and more. We are also commencing development of the biofuels applications of the MDT patents through our separate subsidiary, VG Energy.

 ??About Viral Genetics, Inc.?? Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com. ?? About VG Energy?? VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc.

Using its Metabolic Disruption Technology (MDT), Viral Genetics` cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency:

namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit www.vgenergy.net

Please Read carefully before buying any stock. www.fastmovingstock.com has a no tolerance spam policy, we will not sell or re distribute your email to any third party.

If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members. Verify all claims and do your own due diligence. www.fastmovingstock.comprofiles are not a solicitation or recommendation to buy, sell or hold securities. www.fastmovingstock.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. www.fastmovingstock.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies.

The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

In order to be in full compliance with the Securities Act of 1933, Section 17(b), www.fastmovingstock.com is owned and operated by www.fastmovingstock.com. Neither www.fastmovingstock.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since www.fastmovingstock.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in www.fastmovingstock.com statements and opinions and such statements and opinions cannot be considered independent. www.fastmovingstock.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.www.fastmovingstock.com services are often paid for using free-trading shares. Www.fastmovingstock.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Read full disclaimer at http://www.fastmovingstock.com/disclaimer/